Short-read Sequencing Market

In this report, the Short-read Sequencing Market has been segmented by Technology, Workflow,Product, Application, End Use, and Geography.

Short-read Sequencing Market, Segmentation by Technology

The Short-read Sequencing Market has been segmented by Technology into Next-Generation Sequencing and Sanger Sequencing.

Next-Generation Sequencing (NGS)

Next-Generation Sequencing commands a dominant position in the short-read sequencing industry, representing over 85% of the total market. Renowned for its high throughput, cost-effectiveness, and rapid processing, NGS empowers large-scale genomic research and precision medicine programs. With the ability to generate billions of short reads in a single run, coupled with continual improvements in sequencing chemistry and bioinformatics, it offers unmatched accuracy and scalability.

Sanger Sequencing

While Sanger Sequencing holds under 15% of the market share, it remains indispensable for specific, high-precision applications. Its strength lies in targeted sequencing, validation of NGS data, and small-scale clinical diagnostics. The method’s proven reliability, ability to deliver longer reads, and well-established workflows ensure it continues to serve as a trusted tool in confirmatory testing and specialized genetic studies.

Short-read Sequencing Market, Segmentation by Workflow

The Short-read Sequencing Market has been segmented by Workflow into Pre-Sequencing, Sequencing, Data Analysis.

Pre-Sequencing

Pre-sequencing, which covers crucial steps like sample preparation and library creation, makes up roughly 30% of the short-read sequencing workflow market. This stage plays a pivotal role in maintaining sample integrity and ensuring accurate downstream results. Ongoing advancements in automation and high-quality reagents are minimizing errors, enhancing reproducibility, and reducing processing times.

Sequencing

Sequencing remains the dominant workflow phase, contributing to over 50% of the market share. This step focuses on decoding nucleotide sequences using cutting-edge platforms, with Next-Generation Sequencing leading the way. The push for faster, high-throughput technologies is fueled by expanding genomic research, clinical diagnostics, and personalized medicine applications.

Data Analysis

Data analysis, representing about 20% of the market, has become increasingly vital as sequencing projects produce massive volumes of data. This stage involves sequence alignment, variant detection, and biological interpretation to deliver actionable insights. Innovations in AI-powered bioinformatics and cloud computing are enabling faster, more precise, and scalable analysis.

Short-read Sequencing Market, Segmentation by Product

The Short-read Sequencing Market has been segmented by Instruments, Consumables, and Services

Instruments

Instruments contribute around 35% to the short-read sequencing market, covering advanced sequencing machines and supporting hardware. Growing demand for high-speed, high-accuracy, and scalable platforms is driving innovation in this segment. The introduction of compact, high-throughput devices is making sequencing more accessible across research facilities, hospitals, and diagnostic laboratories.

Consumables

Consumables lead the market with over 45% share, comprising essential products such as reagents, kits, and flow cells required for each sequencing run. The segment benefits from consistent, repeat-use demand driven by rising sequencing throughput in research and clinical diagnostics. Technological improvements in reagent stability and workflow efficiency are further propelling growth.

Services

Services account for roughly 20% of the short-read sequencing market, offering outsourced sequencing, bioinformatics expertise, and data management solutions. Many organizations are opting for specialized providers to reduce costs and avoid heavy infrastructure investments. The increasing use of cloud-based platforms is improving service speed, scalability, and global accessibility.

Short-read Sequencing Market, Segmentation by Application

The Short-read Sequencing Market has been segmented by Application into Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing & Resequencing- (DNA-based, RNA-based), Others

Whole Genome Sequencing (WGS)

Whole Genome Sequencing commands roughly 40% of the short-read sequencing application market. Offering complete coverage of the entire genome, it supports breakthroughs in genetic variation analysis, disease research, and evolutionary studies. WGS is a cornerstone in large-scale population genomics, precision medicine, and rare disease investigations.

Whole Exome Sequencing (WES)

Whole Exome Sequencing holds close to 25% of the market by focusing exclusively on protein-coding regions, which represent just 1–2% of the genome but contain most disease-causing mutations. This cost-effective method is widely adopted in clinical diagnostics, rare disease detection, and gene-focused research.

Targeted Sequencing & Resequencing – DNA-based

DNA-based targeted sequencing & resequencing account for about 20% of the market. By zeroing in on specific genomic regions, it delivers deep coverage and high precision for detecting mutations and structural variants. Key uses include oncology, hereditary disease screening, and pharmacogenomics.

Targeted Sequencing & Resequencing – RNA-based

RNA-based targeted sequencing & resequencing make up nearly 10% of the market. This method provides insights into gene expression, transcriptome analysis, and RNA-level genetic changes. It plays an essential role in cancer biology, infectious disease research, and studies on gene regulation.

Others

The “Others” category represents around 5% of the market, covering emerging fields like metagenomics, epigenomics, and microbial diversity studies. These approaches are expanding in environmental science, agriculture, and microbiome research, opening new avenues for sequencing technology applications.

Short-read Sequencing Market, Segmentation by End Use

The Short-read Sequencing Market has been segmented by End Use into Academic Research, Clinical Research, Hospitals & Clinics, Pharma & Biotech Entities and Other.

Academic Research

Academic research dominates the short-read sequencing market with about 35% share. Universities and research institutes employ these technologies for genomics, transcriptomics, and evolutionary biology studies. Expanding government and private funding for academic genomics projects continues to boost adoption and innovation in this space.

Clinical Research

Clinical research represents approximately 25% of the market, playing a critical role in disease mechanism analysis, biomarker discovery, and clinical trial support. The growing emphasis on precision medicine is a key driver, pushing demand for advanced sequencing in clinical settings.

Hospitals & Clinics

Hospitals and clinics account for around 20% of the market, focusing primarily on diagnostic sequencing for rare disease detection, oncology profiling, and infectious disease identification. The steady integration of sequencing into routine diagnostics is expanding adoption in healthcare environments.

Pharma & Biotech Entities

Pharma and biotech entities hold roughly 15% of the market, using short-read sequencing for drug discovery, companion diagnostics, and personalized therapy development. Strategic collaborations between biopharma firms and sequencing technology providers are enhancing capabilities in targeted drug development.

Other

The “Other” category makes up about 5% of the market, spanning applications in agriculture, environmental research, and forensic science. Rising interdisciplinary adoption is gradually strengthening its contribution to the market landscape.

Short-read Sequencing Market, Segmentation by Geography

In this report, the Short-read Sequencing Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Short-read Sequencing Market Share (%), by Geographical Region

As of the most recent data from the previous year, the global short-read sequencing market share by geographical region can be outlined as follows:

North America

North America dominates the short-read sequencing market with around 40% share, driven by robust research infrastructure, advanced healthcare systems, and significant genomics investments. The United States leads the region, benefiting from high adoption rates in both clinical diagnostics and academic research.

Europe

Europe accounts for roughly 25% of the market, led by the UK, Germany, and France. Strong government funding, collaborative research initiatives, and expanding precision medicine applications are fueling demand for short-read sequencing technologies across the region.

Asia Pacific

Asia Pacific holds close to 20% of the market, emerging as one of the fastest-growing regions. Countries such as China, Japan, and India are investing heavily in genomic research, healthcare modernization, and large-scale sequencing projects, driving rapid adoption.

Middle East and Africa

Middle East and Africa capture about 8% of the market. While adoption is still in its early phases, increasing healthcare infrastructure investment and the gradual integration of genetic testing in clinical practice are creating growth opportunities.

Latin America

Latin America represents nearly 7% of the market, with Brazil and Mexico leading the way. Growth is supported by rising genomic medicine awareness and partnerships with global research institutions, although cost-related barriers continue to restrict widespread implementation.

This report provides an in depth analysis of various factors that impact the dynamics of Global Short-read Sequencing Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers

• Advancements in Sequencing Technologies
• Increasing Applications in Clinical Diagnostics
• Rising Demand for Personalized Medicine

• Expanding Research and Development Activities - Expanding research and development (R&D) activities are a significant driver of growth in the global short-read sequencing market. As the field of genomics continues to evolve, there is an increasing emphasis on understanding the genetic basis of diseases, improving diagnostic tools, and developing targeted therapies. This has led to substantial investments in R&D by both public and private sectors.

  Academic institutions, research organizations, and biotechnology companies are at the forefront of these efforts, utilizing short-read sequencing to conduct in-depth genetic studies. These activities include large-scale genome projects, cancer genomics research, and studies on rare genetic disorders. The high accuracy and efficiency of short-read sequencing make it an indispensable tool for these complex analyses.

  The pharmaceutical industry is leveraging short-read sequencing in drug discovery and development. By identifying genetic mutations and biomarkers associated with diseases, companies can develop more effective and personalized treatments. This not only enhances the therapeutic outcomes but also reduces the time and cost associated with bringing new drugs to market.

  Government initiatives and funding programs also play a crucial role in promoting R&D activities. Many countries have launched national genomics projects aimed at advancing precision medicine and improving public health. These initiatives provide a significant boost to the short-read sequencing market by fostering innovation and encouraging the adoption of advanced genomic technologies.

Restraints

• High Initial Investment Costs
• Data Management and Storage Challenges
• Limited Skilled Workforce

• Regulatory and Ethical Concerns - Regulatory and ethical concerns present significant challenges to the growth of the global short-read sequencing market. The regulatory landscape for genomic technologies is complex and varies widely across different countries, affecting the development, approval, and commercialization of short-read sequencing platforms and associated products.

  In many regions, stringent regulatory requirements necessitate extensive clinical validation and compliance with safety standards before new sequencing technologies can be approved for clinical use. These processes can be time-consuming and costly, potentially delaying the introduction of innovative sequencing solutions to the market. Additionally, the lack of harmonization in regulatory frameworks across different jurisdictions can complicate global market entry strategies for companies, requiring them to navigate diverse regulatory landscapes and adapt to varying compliance requirements.

  Ethical concerns also play a crucial role in the deployment and adoption of short-read sequencing technologies. Issues related to patient privacy, data security, and informed consent are paramount, as sequencing involves the collection and analysis of sensitive genetic information. Ensuring that patient data is protected and used ethically is essential to maintaining public trust and acceptance of genomic technologies. Breaches of data security or misuse of genetic information can lead to significant ethical and legal repercussions, potentially undermining the market's credibility.

Opportunity

• Development of Cost-effective Sequencing Solutions
• Expansion in Emerging Markets
• Integration with Artificial Intelligence and Big Data Analytics

• Collaborations and Partnerships in Genomic Research - Collaborations and partnerships in genomic research are pivotal for driving innovation and growth in the global short-read sequencing market. These alliances bring together diverse expertise and resources, facilitating advancements in genomic technologies and expanding the applications of short-read sequencing across various fields.

  Academic institutions, research organizations, and biotechnology companies are increasingly collaborating to leverage their collective strengths. These partnerships enable the sharing of knowledge, technologies, and data, accelerating the pace of discovery and development in genomics. For instance, large-scale genome sequencing projects often involve multiple institutions and researchers working together to decode complex genetic information, leading to significant breakthroughs in understanding diseases and genetic variations.

  Pharmaceutical companies also play a crucial role in these collaborations. By partnering with genomic research organizations, they can access cutting-edge sequencing technologies and genetic insights that are crucial for drug discovery and development. These collaborations help identify genetic markers associated with diseases, paving the way for the development of targeted therapies and personalized medicine approaches. Such partnerships can significantly reduce the time and cost involved in bringing new drugs to market, enhancing therapeutic outcomes and patient care.

  Government agencies and public health organizations are also key stakeholders in collaborative efforts. National and international initiatives, such as the Human Genome Project and the 100,000 Genomes Project, demonstrate the power of collaborative research in achieving large-scale genomic advancements. These initiatives provide valuable data and infrastructure that benefit the entire genomic research community, fostering further innovation and application of short-read sequencing technologies.

Key players in Global Short-read Sequencing Market include :

• Thermo Fisher Scientific
• F. Hoffmann-La Roche AG
• Illumina
• Genewiz
• Genscript Biotech Corporation
• 10x Genomics
• Qiagen
• Agilent Technologies
• BGI Genomics
• Fasteris SA

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis